{"DataElement":{"publicId":"12943979","version":"1","preferredName":"Systematic Prostate Biopsy NCCN Prostate Cancer Risk Stratification Diagnostic Imaging Computed Tomography Category","preferredDefinition":"The NCCN prostate cancer risk stratification group using systematic prostate biopsy as determined by diagnostic CT scan.","longName":"SYSTBX_NCCN_DXCT_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"12940042","version":"1","preferredName":"Systematic Prostate Biopsy National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease Diagnostic Imaging Computed Tomography","preferredDefinition":"A method of needle biopsy where prostate tissue samples are taken from multiple predetermined locations, without targeting specific areas._A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.:Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation._A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.","longName":"12940027v1.00:12940041v1.00","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"12940027","version":"1","preferredName":"Systematic Prostate Biopsy National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease","preferredDefinition":"A method of needle biopsy where prostate tissue samples are taken from multiple predetermined locations, without targeting specific areas._A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.","longName":"C192890:C181084","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systematic Prostate Biopsy","conceptCode":"C192890","definition":"A method of needle biopsy where prostate tissue samples are taken from multiple predetermined locations, without targeting specific areas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease","conceptCode":"C181084","definition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CFA0F3-0494-5A30-E053-731AD00A9CA3","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"12940041","version":"1","preferredName":"Diagnostic Imaging Computed Tomography","preferredDefinition":"Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation._A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.","longName":"C16502:C17204","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnostic Imaging","conceptCode":"C16502","definition":"Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Computed Tomography","conceptCode":"C17204","definition":"A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CFAA4E-99A4-5EA9-E053-731AD00AEF2E","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CFAA4E-99A6-5EA9-E053-731AD00AEF2E","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12939854","version":"1","preferredName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease Category","preferredDefinition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy._A grouping of items based on some commonality or by user defined characteristics.","longName":"PC_RSK_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"45","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Very Low Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940069","version":"1","preferredName":"NCCN Prostate Cancer Very Low Risk Group","longName":"12940069v1.00","preferredDefinition":"A prostate cancer risk group characterized by: clinical stage T1c, biopsy Gleason score of 6 or less, and PSA level less than 10.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Very Low Risk Group","conceptCode":"C192873","definition":"A prostate cancer risk group characterized by: clinical stage T1c, biopsy Gleason score of 6 or less, and PSA level less than 10.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116C-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117C-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Low Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940070","version":"1","preferredName":"NCCN Prostate Cancer Low Risk Group","longName":"12940070v1.00","preferredDefinition":"A prostate cancer risk group characterized by: clinical stage T1-T2a, biopsy Gleason score of 6 or less, and PSA level less than 10 ng/mL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Low Risk Group","conceptCode":"C192874","definition":"A prostate cancer risk group characterized by: clinical stage T1-T2a, biopsy Gleason score of 6 or less, and PSA level less than 10 ng/mL.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116D-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117D-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Favorable-Intermediate Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940071","version":"1","preferredName":"NCCN Prostate Cancer Favorable-Intermediate Risk Group","longName":"12940071v1.00","preferredDefinition":"A prostate cancer risk group characterized by: Gleason score of 3 + 4 or less, positive biopsy cores less than 50%, and at most 1 determinant of intermediate risk.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Favorable-Intermediate Risk Group","conceptCode":"C192876","definition":"A prostate cancer risk group characterized by: Gleason score of 3 + 4 or less, positive biopsy cores less than 50%, and at most 1 determinant of intermediate risk.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116E-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117E-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Unfavorable-Intermediate Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940072","version":"1","preferredName":"NCCN Prostate Cancer Unfavorable-Intermediate Risk Group","longName":"12940072v1.00","preferredDefinition":"A prostate cancer risk group characterized by: primary Gleason pattern 4, positive biopsy cores greater than or equal to 50%, or multiple determinants of intermediate risk.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Unfavorable-Intermediate Risk Group","conceptCode":"C192877","definition":"A prostate cancer risk group characterized by: primary Gleason pattern 4, positive biopsy cores greater than or equal to 50%, or multiple determinants of intermediate risk.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116F-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117F-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"High Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940073","version":"1","preferredName":"NCCN Prostate Cancer High Risk Group","longName":"12940073v1.00","preferredDefinition":"A prostate cancer risk group characterized by: clinical stage T3a, or biopsy Gleason score 8-10, or PSA level greater than 20 ng/mL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer High Risk Group","conceptCode":"C192878","definition":"A prostate cancer risk group characterized by: clinical stage T3a, or biopsy Gleason score 8-10, or PSA level greater than 20 ng/mL.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-1170-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-1180-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Very High Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940074","version":"1","preferredName":"NCCN Prostate Cancer Very High Risk Group","longName":"12940074v1.00","preferredDefinition":"A prostate cancer risk group characterized by clinical stage T3b or T4, biopsy Gleason score 9 or 10, or N1, N2, or N3 with any stage T, or M1 with any stage T.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Very High Risk Group","conceptCode":"C192879","definition":"A prostate cancer risk group characterized by clinical stage T3b or T4, biopsy Gleason score 9 or 10, or N1, N2, or N3 with any stage T, or M1 with any stage T.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-1171-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-1181-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12939853","version":"1","preferredName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease Category","preferredDefinition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy._A grouping of items based on some commonality or by user defined characteristics.","longName":"12939853v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease","conceptCode":"C181084","definition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F7DC-ACE6-6510-E053-731AD00A15B5","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F7DC-ACED-6510-E053-731AD00A15B5","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Diagnostic CT (Risk Stratification Using Systematic Biopsy)","type":"Preferred Question Text","description":"Diagnostic CT (Risk Stratification Using Systematic Biopsy)","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D11B44-0E21-0AD0-E053-731AD00A29A8","latestVersionIndicator":"Yes","beginDate":"2023-03-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"}}